| Project/Area Number |
22592242
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 一般 |
|---|
| Research Field |
Surgical dentistry
|
|---|
| Research Institution | Sapporo Medical University |
|---|
Principal Investigator |
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
YAMAGUCHI Akira 札幌医科大学, 医学部, 講師 (10210353)
KOBAYASHI Jyunichi 札幌医科大学, 医学部, 助教 (80404739)
YAMAMOTO Takashi 札幌医科大学, 医学部, 研究員 (50448594)
道振 義貴 札幌医科大学, 医学部, 研究員 (00457722)
佐々木 敬則 札幌医科大学, 医学部, 研究員 (50548732)
藤野 準己 札幌医科大学, 医学部, 研究員 (60620945)
|
|---|
| Project Period (FY) |
2010 – 2012
|
| Project Status |
Completed (Fiscal Year 2012)
|
| Budget Amount *help |
¥4,550,000 (Direct Cost: ¥3,500,000、Indirect Cost: ¥1,050,000)
Fiscal Year 2012: ¥910,000 (Direct Cost: ¥700,000、Indirect Cost: ¥210,000)
Fiscal Year 2011: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2010: ¥2,340,000 (Direct Cost: ¥1,800,000、Indirect Cost: ¥540,000)
|
|---|
| Keywords | がんペプチドワクチン / がん抗原 / 口腔がん / サバイビン / がん免疫 / 癌 / 免疫学 / ワクチン |
|---|
| Research Abstract |
We have confirmed the safety and efficacy of a cancer peptide vaccine therapy using a survivin2B-derived peptide decomposed from a survivin protein that is highly expressed in many malignancies. Furthermore, a clinical trial indicated that when using the peptide in conjunction with stimulants, a stronger immune effect could be obtained than from the peptide alone. The trial also confirmed the safety of the vaccine therapy. In the quest to develop a cancer peptide vaccine other than survivin, we have identified molecules that are highly expressed in cancer stem cells of the oral cavity, and established a foundation towards a more effective clinical application of cancer peptide vaccine therapy.
|
